Ixazomib-cyclophosphamide-dexamethasone combo effective for multiple myeloma
The combination of ixazomib, cyclophosphamide and dexamethasone is well-tolerated and effective for newly diagnosed myeloma, a recent study has shown.
The phase 1/2 study included 48 patients newly diagnosed with multiple myeloma (median age 64.5 years; 52.1 percent male), of whom 45 (median age 64.0; 53.3 percent male) subsequently received the phase 2 dose. The maximum tolerated dose and the rate of complete or very good partial responses (VGPR) were the primary endpoints for the first and second phases of the study, respectively.
Majority of the patients (77 percent; n=37) reported at least a confirmed partial response, with 35 percent achieving a VGPR or better. The median time to response was 1.9 months, and the depth of response increased as participants received more cycles of therapy. The overall response rate at the end of four cycles was 71 percent.
The median progression-free (PFS) and overall (OS) survival were not reached for the whole study sample, while the 18-month PGS and OS rates were 81 percent and 96 percent. The 1-year OS was 100 percent.
Over a median of seven therapy cycles, 100 percent of the participants reported at least one adverse event of any grade. Grade 3 or 4 adverse events that were considered to be at least potentially associated to the therapy was observed in 88 percent of the participants.
The most common grade ≥2 adverse event included nausea, anaemia, neutropoenia, leukopoenia and lymphopoenia.